Get the Stockscreener App
1.86
0.53%
-0.01
After Hours:
1.86
TherapeuticsMD Inc stock is currently priced at $1.86, with a 24-hour trading volume of 6,199.
It has seen a -0.53% decreased in the last 24 hours and a -17.33% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.88 pivot point. If it approaches the $1.86 support level, significant changes may occur.
Previous Close:
$1.87
Open:
$1.87
24h Volume:
6,199
Market Cap:
$21.45M
Revenue:
$69.37M
Net Income/Loss:
$68.31M
P/E Ratio:
0.4143
EPS:
4.49
Net Cash Flow:
$-1.32M
1W Performance:
+0.00%
1M Performance:
-17.33%
6M Performance:
-7.00%
1Y Performance:
-47.31%
1D Range:
$1.86
$1.90
52W Range:
$1.86
$4.725
TherapeuticsMD Inc Stock (TXMD) Company Profile
Name
TherapeuticsMD Inc
Sector
Phone
561 961 1900
Address
951 Yamato Road, Suite 220, Boca Raton, FL
TherapeuticsMD Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
TherapeuticsMD Inc Stock (TXMD) Latest News
TherapeuticsMD Inc Stock (TXMD) Financials Data
TherapeuticsMD Inc (TXMD) Revenue 2024
TXMD reported a revenue (TTM) of $69.37 million for the quarter ending September 30, 2023, a +207.87% rise year-over-year.
TherapeuticsMD Inc (TXMD) Net Income 2024
TXMD net income (TTM) was $68.31 million for the quarter ending September 30, 2023, a +888.31% increase year-over-year.
TherapeuticsMD Inc (TXMD) Cash Flow 2024
TXMD recorded a free cash flow (TTM) of -$1.32 million for the quarter ending September 30, 2023, a +97.88% increase year-over-year.
TherapeuticsMD Inc (TXMD) Earnings per Share 2024
TXMD earnings per share (TTM) was $7.17 for the quarter ending September 30, 2023, a +817.00% growth year-over-year.
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
1.69%
1.28%
Cap:
|
Volume (24h):